Email Alert | RSS    帮助

中国防痨杂志 ›› 2005, Vol. 27 ›› Issue (6): 389-392.

• 论著 • 上一篇    下一篇

微卡辅助治疗耐多药肺结核的临床研究

姚恒波;尚好珍;郭磊;王永亮;冯菊梅;马娟玫;   

  1. 新乡医学院结核病研究所 卫辉 453100;
  • 出版日期:2005-06-10 发布日期:2005-11-03

The observation of the effect of the treatment of multi?drug resistant pulmonary tuberculosis with M Vaccae

Yao Hengbo,Shang Haozhen,Guo Lei,et al.   

  1. The Tuberculosis Instituted of XinXiang Medical College,HeNan Weihui,453100,China
  • Online:2005-06-10 Published:2005-11-03

摘要: 目的 探讨评价微卡(母牛分枝杆菌菌苗)治疗耐多药肺结核的疗效。方法 60例耐多药肺结核患者按入院先后顺序分为微卡加化疗组即治疗组,与单纯化疗组即对照组。化疗方案均为3PaL2AKZThV/15PaL2ZThV。治疗组为病人头3个月每15d肌注微卡(22.5μg),随后的3个月每月肌注1次微卡。观察2组治疗后肺部病灶吸收情况、痰菌阴转情况、症状改善情况、免疫功能变化情况。结果 治疗组与对照组3个月时痰菌阴转率分别为56.6%和26.6%,18个月时为93.3%和73.3%有显著差异(P<0.05);X线吸收率及空洞缩小、闭合率均有明显差异P<0.05;CD4+、CD4+/CD8+9个月时治疗组与同组治疗前及对照组均有显著差异P<0.05。结论 微卡能调节免疫功能,提高痰菌阴转率,有助于病灶吸收空洞闭合,可作为耐多药肺结核化疗的辅助治疗。

关键词: 结核, 抗多种药物性/治疗

Abstract: Objective To evaluate the assistant value of Vaccae on treatment of multi-durg resistance pulmonary tuberculosis. Method Sixty cases with multi-durg resistance pulmonary tuberculosis were divided randomly into the treatment group and the control group.The cases in 2 groups were treated by the same chemotherapy regimen with 3PaL2AkZThV/15PaL2ZThV.in the same time.The treatment group cases were injected vaccae (22.5μg) every 15-day in the first three month,then observe the change of the market absorption,sputum conversion,symptom improvement,immune function in the two groups after the treatment. Results There was significant difference on the rates of sputum smear negative conversion.In the two groups,they were 56.6% and 26.6% at the end of 3 months,93.3% and 73.3%at the end of 18 months respectively,there were obvious difference of CD4,CD4/CD8 focus absorption and closure rates of cavities at the end of 9 months between the treatment group and control group. Conclusion Vaccae is helpful to the immune function,sputum negative conversion and the absorption of focus,it has a adjustment treatment of multi-drug cases.

Key words: Tuberculosis, multidrug resistance/therapy